MJNA is tanking hard. Beyond stop-losses being triggered, there are many potential fundamental reasons - weak Q3 results, the CANV dilution, the product safety accusations and the SEC inquiry (as of June 17th and disclosed in August through the OTC disclosure statement). It is the latter where I would like to share my thoughts.
MJNA first announced its own internal investigation earlier this year. It began in January, as was disclosed in the Q1 filing (note that this should have been disclosed as a subsequent event in the annual report and wasn't). Keep in mind that every single director at that time has left the board with the exception of Michelle Sides, the Chairman and COO (rather alarming). Here is what was disclosed: